Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > Horrific value destruction
View:
Post by ZoranSto on Jun 20, 2024 10:45am

Horrific value destruction

This has been dropping constantly for the past couple of weeks and absolutley no comments from Gilles......what is going on?????
Comment by Hopeforthebest on Jun 20, 2024 12:14pm
Honestly ZoranSto do you expect anything less from gagnon, After all as proph pointed out, this stock was once at $300US plus and getting it were it is today takes a special type of talent to ensure that you (gagnon) continues to get millions$$$$$ while the shareholders lose their investments. When proph, aka gagnon talks about merger of equals who would of thought that what he actually meant was ...more  
Comment by ZoranSto on Jun 20, 2024 2:33pm
It will be voting time again and I think Oats is pissed as well so maybe this vote we will be able to make some changes. And as usual not one insider buy....
Comment by lscfa on Jun 20, 2024 2:41pm
Vote Gagnon out at next agm
Comment by lscfa on Jun 20, 2024 3:32pm
Sell off must be CZO shareholders selling their newly acquired AEZS shares after merger.
Comment by Ciao on Jun 20, 2024 3:56pm
Could be the exisitng AEZS shareholders as well who essentially got free shares to up their holdings by 50% "Additionally, as part of the Transaction, Aeterna will issue to its shareholders immediately prior to the closing of the Transaction, 0.47698 of a share purchase warrant (“Transaction Warrant”) for each Aeterna common share held as of such date. Each Transaction Warrant will have a ...more  
Comment by Hopeforthebest on Jun 20, 2024 4:06pm
And proph aka gagnon has spouted along a merger of equals, I guess some are more equal than others.  as for oats being pissed, well cry me a river he had more than enough opportunities to right this sinking ship and exercised not too. He believed the garbage and now will be holding the majority of the garbage. the only way to right ship is to vote no and clean house of theses crooks but ...more  
Comment by archeo753 on Jun 20, 2024 4:25pm
Premerger CZO shares now worth $0.1425.  Is that an all time low?  Zero reson for any new shareholders to purchase AEZS shares so dramatic decline on very low volume.  A new name and a complete reset is deperately needed. 
Comment by prophetoffactz on Jun 20, 2024 4:23pm
The shares outstanding on Stockhouse and others say about 3.06 million AEZS shares outstanding. That doesn't seem to take into account the AEZS warrants and conversion. Maybe those shares from the warrants are being distributed now and sold. I'm also seeing a number of stocks being sold down and I wonder if the June 25 capital gains tax deadline is causing portfolio rebalancing.  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities